- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01950312
The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
February 2, 2016 updated by: XOMA (US) LLC
An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New Hyde Park, New York, United States, 11040
- Long Island Jewish Medical Center, Hearing & Speech Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Autoimmune Inner Ear Disease with active deterioration in at least one ear
- Failure to respond to a trial of high-dose corticosteroid therapy
- Contraceptive measures adequate to prevent pregnancy during the study
Exclusion Criteria:
- Evidence of retrocochlear pathology (vestibular schwannoma) or inner ear malformation (Mondini Malformation or Enlarged Vestibular Aqueduct)
- History of active or chronic infections
- Currently receiving, or having received treatment for a malignancy in the past three years
- Hearing loss that coincides with significant, disabling episodes of vertigo
- History of allergic or anaphylactic reactions to monoclonal antibodies
- Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: gevokizumab
Solution for subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improved hearing threshold, as defined by an improvement in either the PTA (Pure Tone Average) of >=5 dB (Decibel), or 12% in the WRS (Word Recognition Score)
Time Frame: Day 28 to Day 84
|
Day 28 to Day 84
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
September 20, 2013
First Submitted That Met QC Criteria
September 20, 2013
First Posted (Estimate)
September 25, 2013
Study Record Updates
Last Update Posted (Estimate)
February 3, 2016
Last Update Submitted That Met QC Criteria
February 2, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- X052180
- R33DC011827 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Inner Ear Disease
-
Northwell HealthSwedish Orphan BiovitrumRecruitingMeniere's Disease | Autoimmune Inner Ear DiseaseUnited States
-
House Research InstituteJanssen Services, LLCTerminatedAutoimmune Inner Ear Disease
-
National Institute on Deafness and Other Communication...RecruitingMeniere's Disease | Enlarged Vestibular Aqueduct Syndrome | Autoimmune Inner Ear DiseaseUnited States
-
Simbec ResearchSensorion SACompletedInner Ear Diseases
-
Andrea VambutasNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedSensorineural Hearing Loss | Autoimmune Inner Ear DiseaseUnited States
-
Eytan A. DavidActive, not recruitingDizziness | Equilibrium; Disorder, Labyrinth | Inner Ear Injury | Inner Ear DiseaseCanada
-
Simbec ResearchSensorionCompleted
-
Universidad de ZaragozaAragon Institute of Health SciencesCompletedEquilibrium; Disorder, Labyrinth | Spatial Navigation | Inner Ear DiseaseSpain
-
University Hospital, GrenobleNot yet recruitingInner Ear ; Meniere's Disease; Imaging
-
Nordsjaellands HospitalHvidovre University HospitalUnknownHearing Loss, Sensorineural | CNS Infection | Vestibular Abnormality | Inner Ear Hearing Loss | Inner Ear InflammationDenmark
Clinical Trials on gevokizumab
-
Institut de Recherches Internationales ServierTerminatedChronic UveitisItaly, United Kingdom, Korea, Republic of, Portugal, Taiwan, Australia, Turkey, Tunisia, Austria, France, Germany, Greece, Spain
-
National Eye Institute (NEI)The Emmes Company, LLCCompleted
-
XOMA (US) LLCTerminatedPyoderma GangrenosumUnited States
-
XOMA (US) LLCTerminatedPyoderma GangrenosumUnited States, Australia, Canada
-
XOMA (US) LLCInstitut de Recherches Internationales ServierTerminatedUveitisUnited States, France, Germany, Poland, United Kingdom, China, Spain, Mexico, Portugal, Turkey, Israel, Canada, South Africa, Taiwan, Argentina, Russian Federation, Australia, Italy, Brazil, Armenia, Greece, Tunisia
-
XOMA (US) LLCInstitut de Recherches Internationales ServierTerminatedUveitisUnited States, France, Germany, Poland, United Kingdom, China, Spain, Mexico, Portugal, Turkey, Israel, Korea, Republic of, South Africa, Taiwan, Argentina, Brazil, Austria, Russian Federation, Australia, Armenia, Greece, Tunisia
-
XOMA (US) LLCTerminatedPyoderma GangrenosumUnited States, Australia, Canada
-
XOMA (US) LLCCompletedPyoderma GangrenosumUnited States
-
XOMA (US) LLCCompletedOsteoarthritisUnited States
-
XOMA (US) LLCCompletedOsteoarthritisUnited States